Advertisement
Screener

PTC Therapeutics, Inc. (PTCT) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

PTC Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities

PTC Therapeutics, Inc. (PTCT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$31.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-07-30

  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $37.50M.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$68.71M, a 471.38% decline year-over-year.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $108.08M.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$43.20M, a 336.29% decline year-over-year.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $71.74M.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$33.32M, a 168.92% decline from fiscal 2023.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $48.35M, a 75.54% increase from fiscal 2022.
  • PTC Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $27.54M, a 39.68% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed
2026-06-30$37.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30
-$31.21M
10-Q · filed 2026-07-30
$76.87M
derived: sum of 3 quarters · filed 2026-07-30
$33.66M
derived: sum of 4 quarters · filed 2026-07-30
2026-03-31-$68.71M
10-Q · filed 2026-05-07
$39.37M
derived: sum of 2 quarters · filed 2026-05-07
-$3.84M
derived: sum of 3 quarters · filed 2026-05-07
-$15.47M
derived: sum of 4 quarters · filed 2026-07-30
2025-12-31$108.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$64.88M
derived: sum of 2 quarters · filed 2026-02-19
$53.24M
derived: sum of 3 quarters · filed 2026-07-30
$71.74M
10-K · filed 2026-02-19
2025-09-30-$43.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$54.84M
derived: sum of 2 quarters · filed 2026-07-30
-$36.34M
10-Q · filed 2025-11-04
-$69.25M
derived: sum of 4 quarters · filed 2026-07-30
2025-06-30-$11.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30
$6.86M
10-Q · filed 2026-07-30
-$26.04M
derived: sum of 3 quarters · filed 2026-07-30
-$7.76M
derived: sum of 4 quarters · filed 2026-07-30
2025-03-31$18.50M
10-Q · filed 2026-05-07
-$14.40M
derived: sum of 2 quarters · filed 2026-05-07
$3.88M
derived: sum of 3 quarters · filed 2026-05-07
-$9.43M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$32.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
-$14.62M
derived: sum of 2 quarters · filed 2026-02-19
-$27.93M
derived: sum of 3 quarters · filed 2026-02-19
-$33.32M
10-K · filed 2026-02-19
2024-09-30$18.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$4.97M
derived: sum of 2 quarters · filed 2025-11-04
-$417.00K
10-Q · filed 2025-11-04
$7.50M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30-$13.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$18.70M
10-Q · filed 2025-08-07
-$10.79M
derived: sum of 3 quarters · filed 2026-02-19
-$2.79M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31-$5.39M
10-Q · filed 2025-05-06
$2.52M
derived: sum of 2 quarters · filed 2026-02-19
$10.52M
derived: sum of 3 quarters · filed 2026-02-19
$9.43M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31$7.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$15.91M
derived: sum of 2 quarters · filed 2026-02-19
$14.82M
derived: sum of 3 quarters · filed 2026-02-19
$48.35M
10-K · filed 2026-02-19
2023-09-30$8.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$6.91M
derived: sum of 2 quarters · filed 2024-11-07
$40.43M
10-Q · filed 2024-11-07
$66.41M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$1.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$32.44M
10-Q · filed 2024-08-08
$58.41M
derived: sum of 3 quarters · filed 2025-02-27
$69.04M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$33.52M
10-Q · filed 2024-04-25
$59.50M
derived: sum of 2 quarters · filed 2025-02-27
$70.13M
derived: sum of 3 quarters · filed 2025-02-27
$91.75M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$25.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$36.60M
derived: sum of 2 quarters · filed 2025-02-27
$58.22M
derived: sum of 3 quarters · filed 2025-02-27
$27.54M
10-K · filed 2025-02-27
2022-09-30$10.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26
$32.25M
derived: sum of 2 quarters · filed 2023-10-26
$1.57M
10-Q · filed 2023-10-26
$38.34M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$21.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$9.06M
10-Q · filed 2023-08-03
$27.71M
derived: sum of 3 quarters · filed 2024-02-29
$45.82M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$30.68M
10-Q · filed 2023-04-27
$6.09M
derived: sum of 2 quarters · filed 2024-02-29
$24.20M
derived: sum of 3 quarters · filed 2024-02-29
$43.73M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$36.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$54.88M
derived: sum of 2 quarters · filed 2024-02-29
$74.42M
derived: sum of 3 quarters · filed 2024-02-29
$45.66M
10-K · filed 2024-02-29
2021-09-30$18.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27
$37.64M
derived: sum of 2 quarters · filed 2022-10-27
$8.89M
10-Q · filed 2022-10-27
$26.46M
derived: sum of 4 quarters · filed 2023-02-21
2021-06-30$19.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$9.22M
10-Q · filed 2022-08-04
$8.35M
derived: sum of 3 quarters · filed 2023-02-21
$70.24M
derived: sum of 4 quarters · filed 2023-02-21
2021-03-31-$28.76M
10-Q · filed 2022-05-03
-$11.18M
derived: sum of 2 quarters · filed 2023-02-21
$50.70M
derived: sum of 3 quarters · filed 2023-02-21
$47.21M
derived: sum of 4 quarters · filed 2023-02-21
2020-12-31$17.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21
$79.46M
derived: sum of 2 quarters · filed 2023-02-21
$75.96M
derived: sum of 3 quarters · filed 2023-02-21
$71.96M
10-K · filed 2023-02-21
$70.80M
10-K · filed 2021-02-25
2020-09-30$61.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
$58.39M
derived: sum of 2 quarters · filed 2021-10-28
$54.39M
10-Q · filed 2021-10-28
$80.53M
derived: sum of 4 quarters · filed 2022-02-22
2020-06-30-$3.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29
-$7.50M
10-Q · filed 2021-07-29
$18.64M
derived: sum of 3 quarters · filed 2022-02-22
$26.89M
derived: sum of 4 quarters · filed 2022-02-22
2020-03-31-$4.00M
10-Q · filed 2021-05-04
$22.14M
derived: sum of 2 quarters · filed 2022-02-22
$30.38M
derived: sum of 3 quarters · filed 2022-02-22
$51.49M
derived: sum of 4 quarters · filed 2022-02-22
2019-12-31$26.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22
$34.38M
derived: sum of 2 quarters · filed 2022-02-22
$55.49M
derived: sum of 3 quarters · filed 2022-02-22
$26.84M
10-K · filed 2022-02-22
2019-09-30$8.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
$29.35M
derived: sum of 2 quarters · filed 2020-10-29
$695.00K
10-Q · filed 2020-10-29
$25.97M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$21.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
-$7.55M
10-Q · filed 2020-08-05
$17.73M
derived: sum of 3 quarters · filed 2021-02-25
$34.11M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$28.65M
10-Q · filed 2020-04-30
-$3.38M
derived: sum of 2 quarters · filed 2021-02-25
$13.00M
derived: sum of 3 quarters · filed 2021-02-25
$22.03M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$25.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$41.65M
derived: sum of 2 quarters · filed 2021-02-25
$50.69M
derived: sum of 3 quarters · filed 2021-02-25
$43.88M
10-K · filed 2021-02-25
2018-09-30$16.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
$25.42M
derived: sum of 2 quarters · filed 2019-10-30
$18.61M
10-Q · filed 2019-10-30
$30.81M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$9.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$2.23M
10-Q · filed 2019-08-06
$14.43M
derived: sum of 3 quarters · filed 2020-03-02
$13.78M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$6.81M
10-Q · filed 2019-05-02
$5.39M
derived: sum of 2 quarters · filed 2020-03-02
$4.75M
derived: sum of 3 quarters · filed 2020-03-02
$21.12M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$12.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$11.56M
derived: sum of 2 quarters · filed 2020-03-02
$27.93M
derived: sum of 3 quarters · filed 2020-03-02
$24.01M
10-K · filed 2020-03-02
2017-09-30-$645.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05
$15.73M
derived: sum of 2 quarters · filed 2018-11-05
$11.81M
10-Q · filed 2018-11-05
$13.99M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$16.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$12.45M
10-Q · filed 2018-08-07
$14.63M
derived: sum of 3 quarters · filed 2019-03-01
$20.15M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$3.92M
10-Q · filed 2018-05-09
-$1.74M
derived: sum of 2 quarters · filed 2019-03-01
$3.77M
derived: sum of 3 quarters · filed 2019-03-01
$2.79M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$2.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$7.69M
derived: sum of 2 quarters · filed 2019-03-01
$6.71M
derived: sum of 3 quarters · filed 2019-03-01
$4.26M
10-K · filed 2019-03-01
2016-09-30$5.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$4.53M
derived: sum of 2 quarters · filed 2017-11-02
$2.08M
10-Q · filed 2017-11-02
$16.19M
derived: sum of 4 quarters · filed 2018-03-06
2016-06-30-$983.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
-$3.44M
10-Q · filed 2017-08-09
$10.68M
derived: sum of 3 quarters · filed 2018-03-06
$19.59M
derived: sum of 4 quarters · filed 2018-03-06
2016-03-31-$2.45M
10-Q · filed 2017-05-08
$11.66M
derived: sum of 2 quarters · filed 2018-03-06
$20.57M
derived: sum of 3 quarters · filed 2018-03-06
$20.12M
derived: sum of 4 quarters · filed 2018-03-06
2015-12-31$14.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06
$23.02M
derived: sum of 2 quarters · filed 2018-03-06
$22.57M
derived: sum of 3 quarters · filed 2018-03-06
$16.98M
10-K · filed 2018-03-06
2015-09-30$8.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$8.46M
derived: sum of 2 quarters · filed 2016-11-03
$2.87M
10-Q · filed 2016-11-03
$15.50M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30-$450.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
-$6.04M
10-Q · filed 2016-08-04
$6.59M
derived: sum of 3 quarters · filed 2017-03-16
$11.74M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31-$5.59M
10-Q · filed 2016-05-05
$7.04M
derived: sum of 2 quarters · filed 2017-03-16
$12.19M
derived: sum of 3 quarters · filed 2017-03-16
$14.80M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$12.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$17.78M
derived: sum of 2 quarters · filed 2017-03-16
$20.39M
derived: sum of 3 quarters · filed 2017-03-16
$16.91M
10-K · filed 2017-03-16
2014-09-30$5.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$7.76M
derived: sum of 2 quarters · filed 2015-11-09
$4.29M
10-Q · filed 2015-11-09
$6.29M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$2.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31
-$866.00K
10-Q · filed 2015-07-31
$1.14M
derived: sum of 3 quarters · filed 2016-02-29
$1.28M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$3.47M
10-Q · filed 2015-05-05
-$1.47M
derived: sum of 2 quarters · filed 2016-02-29
-$1.32M
derived: sum of 3 quarters · filed 2016-02-29
-$2.73M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$2.15M
derived: sum of 2 quarters · filed 2016-02-29
$737.00K
derived: sum of 3 quarters · filed 2016-02-29
$5.18M
10-K · filed 2016-02-29
$5.18M
10-K · filed 2014-03-06
2013-09-30$146.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
-$1.26M
derived: sum of 2 quarters · filed 2014-11-06
$3.18M
10-Q · filed 2014-11-06
$3.18M
10-Q · filed 2013-11-14
$1.90M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30-$1.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$3.04M
10-Q · filed 2014-08-07
$3.03M
10-Q · filed 2013-08-13
$1.76M
derived: sum of 3 quarters · filed 2015-03-02
$1.08M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$4.45M
10-Q · filed 2014-05-06
$3.17M
derived: sum of 2 quarters · filed 2015-03-02
$2.49M
derived: sum of 3 quarters · filed 2015-03-02
2012-12-31-$1.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$1.95M
derived: sum of 2 quarters · filed 2015-03-02
-$6.03M
10-K · filed 2015-03-02
-$6.03M
10-K · filed 2014-03-06
2012-09-30-$675.43K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14
-$4.75M
10-Q · filed 2013-11-14
2012-06-30-$4.07M
10-Q · filed 2013-08-13
2011-12-31-$3.16M
10-K · filed 2014-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Veradermics, Inc (MANE)United States$4.839B
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51